| 24.64 -0.26 (-1.04%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.56 | 1-year : | 34.53 |
| Resists | First : | 25.31 | Second : | 29.56 |
| Pivot price | 23.54  |
|||
| Supports | First : | 22.74 | Second : | 21.15 |
| MAs | MA(5) : | 24.3 |
MA(20) : | 23.46 |
| MA(100) : | 23.16 |
MA(250) : | 23.89  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 87.2 |
D(3) : | 83.9 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 27.63 | Low : | 18.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PCRX ] has closed below upper band by 16.2%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.08 - 25.21 | 25.21 - 25.31 |
| Low: | 23.82 - 23.95 | 23.95 - 24.06 |
| Close: | 24.43 - 24.65 | 24.65 - 24.82 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Tue, 21 Apr 2026
Pacira files Form 144; 2,845-share option sale, 7,714 shares sold (NASDAQ: PCRX) - Stock Titan
Mon, 20 Apr 2026
[144] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Mon, 20 Apr 2026
A Look At Pacira BioSciences (PCRX) Valuation After New EXPAREL Health Economic Data - Sahm
Mon, 20 Apr 2026
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN
Fri, 17 Apr 2026
Pacira (NASDAQ: PCRX) pushes BLUE proxy, flags 2026 pipeline and repurchases - Stock Titan
Thu, 16 Apr 2026
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 - markets.businessinsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 40 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 119.5 (%) |
| Shares Short | 8,060 (K) |
| Shares Short P.Month | 8,470 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.86 |
| Profit Margin | 0.9 % |
| Operating Margin | -1.2 % |
| Return on Assets (ttm) | 1.4 % |
| Return on Equity (ttm) | 0.9 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 11.34 |
| Sales Per Share | 17.94 |
| EBITDA (p.s.) | 3.07 |
| Qtrly Earnings Growth | -88.5 % |
| Operating Cash Flow | 152 (M) |
| Levered Free Cash Flow | 109 (M) |
| PE Ratio | 154 |
| PEG Ratio | 11.2 |
| Price to Book value | 1.46 |
| Price to Sales | 1.37 |
| Price to Cash Flow | 6.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|